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Summary
Background: Alteration of radiation therapy (RT) fractiona-
tion and the combination of chemotherapy (CT) with RT
represent two predominant fields of current research in the
treatment of head and neck carcinomas. To assess the potential
integration of these two fields, a retrospective comparison of
toxicity and treatment outcome was carried out in stage III-IV
patients treated with a concomitant boost RT schedule with or
without CT.
Patients and methods: Fifty-two patients were treated by RT
alone and 35 by RT and CT. In the RT group, there were
significantly fewer T3-4 tumors (56% vs. 88%, P - 0.002) and
higher proportion of planned neck dissections (35% vs. 14%,
P = 0.047). The planned total dose was 69.9 Gy delivered over
5.5 weeks. In 10 cases CT was given before RT and in 25
concomitantly with RT, either alone or with neoadjuvant and/
or adjuvant CT. All patients but two had cisplatin-based
(CDDP, 100 mg/m2) CT, associated in 28 patients with
5-fluorouracil (5-FU, 1000 mg/m2/24 h x 5). The median follow-
up for the surviving patients was 21 and 31 months for the RT
and RT-CT groups respectively.
Results: Grade 3-4 acute toxicity (RTOG) was observed in
73% and 86% of patients, and grade 3 dysphagia in 31% and
57% (P = 0.02) respectively in the RTand RT-CT groups. The
rates of grade 3—4 late complications were similar in the two
groups (5% vs. 12%). At three years, actuarial loco-regional
control (LRC) was 57% and 66% (P = 0.66) and overall survival
was 56% and 47% (P = 0.99) in the RT and RT-CT groups
respectively.
Conclusions: While acute toxicity was higher compared
with RT alone, this accelerated RT schedule was feasible in
association with 5-FU/CDDP, even administered concomi-
tantly. Despite the significant proportion of more advanced
disease in the RT-CT group, LRC was similar to that obtained
by RT alone. Combinations of concomitant boost RT and
chemotherapy merit further investigation in prospective trials.
Key words: accelerated radiotherapy, chemotherapy, head and
neck cancer
Introduction
The prognosis of patients with advanced head and neck
carcinomas treated by standard radiation therapy (RT)
is generally very unfavorable [1-3]. Both the use of un-
conventional fractionation schedules and the adjunction
of chemotherapy to RT are undergoing investigation in
the hope of improving these unsatisfactory results [4-
17]. The encouraging initial results of the concomitant
boost technique [9, 18] led in 1991 to the introduction at
the University Hospital of Geneva of a modified con-
comitant boost schedule in which the boost to the clin-
ically involved sites was delivered in a progressively
accelerated fashion during the last 3.5 weeks of a 5.5
week treatment course. For stage III-IV disease, chemo-
therapy was initially added sequentially prior to RT and
then progressively more frequently in a concomitant
fashion. In order to establish whether or not a con-
comitant boost schedule is compatible with the simulta-
neous administration of chemotherapy, the therapeutic
outcome and toxicity of the combined treatment have
been retrospectively analyzed and compared with those
obtained in a group of patients treated during the same
period with the identical RT regimen but without chemo-
therapy.
Patients and methods
Patients
From January 1991 to October 1995, 87 patients with resectable or
unresectable stage III-IV head and neck carcinomas were treated with
concomitant boost RT, of whom 35 (40%) received combined chemo-
radiotherapy. Compared with patients treated with radiotherapy alone
(RT group), those receiving chemotherapy (RT-CT group) tended to
have bulkier disease. The characteristics of the two groups of patients
are given in Table 1.
Radiation therapy
The treatment schedule planned to deliver a total dose of 69.9 Gy in 41
fractions over a period of 38 days. The basic course, including all
involved sites and areas of potential microscopic disease (generally the
primary tumor area and both sides of the neck down to the clavicles),
was given in daily fractions of 1.8 Gy, five times a week to a total dose
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Table 1. Patient characteristics.
RT group
(52 patients)
RT-CT group
(35 patients)
Mean age (standard devia-
tions)
Gender: male/female
WHO performance status
0-1
2-3
Tumor location
Oral cavity + oropharynx
Hypopharynx + larynx
Nasopharynx
TN stage
Tl-2
NO
Nl-3
AJCC stage
III
IV
61 years (11)
39/13
36(72%)
14(28%)
27(52%)
19(36%)
6(12%)
23(44%)
29(56%)
11(21%)
41(79%)
18(35%)
34 (65%)
54 years (16)
24/11
31(89%)
4(11%)
21(60%)
9(26%)
5(14%)
4(12%)
31(88%)
8(23%)
27(77%)
7(20%)
28 (80%)
0.04
0.1
0.002
0.15
Table 2. Acute morbidities in the two groups of patients.
RT group
(52 patients)
RT-CT group
(35 patients)
Overall grade 3-4
Grade 3—4 mucositis
Grade 3 dysphagia
Hospitalisation
Median duration
(range)
Nasogastric tube or
gastronomy
Median duration
(range)
Median weight loss during
radiotherapy (range)
38 (73%)
34 (65%)
16(31%)
9(17%)
12 days
(4-150)
13(25%)
38 days
(4-150)
4.6 kg (0-14)
30 (86%)
24 (69%)
20 (57%)
14(40%)
19 days
(11-150)
18(51%)
38 days
(11-150)
4 kg (0-11)
0.2
1
0.02
0.02
0.02
continuous 24-hour intravenous infusion of 5-FU (1000 mg/m ) for
five days. During RT, the dose of 5-FU was reduced by 20%-40% in
the second course, according to the severity of the acute mucosal
reactions.
of 50.4 Gy over 5.5 weeks. The boost to initial sites of macroscopic
tumor mvolvement consisted of 13 fractions of 1.5 Gy (19.5 Gy) and
was given as a second daily fraction, starting the last day of the second
week of the basic treatment, in a progressively accelerated fashion
(Figure 1). The minimum interval between the two daily fractions was
six hours.
The larger volume was treated generally with two opposed laterals
and one anterior field, using 6 MV photon beams in most patients. The
field arrangement for the boost was individualized according to the
tumor extent and location. The cervical spinal cord was blocked at a
dose of 45 Gy or less, and irradiation of the posterior neck was then
continued with electrons of appropriate energy. The supraclavicular
lymph nodes generally received a dose of 45-50.4 Gy in 25-28 frac-
tions. No specific technical modifications were used in the group of
patients receiving chemotherapy.
Surgery
No patient received surgery to the primary tumor. Before RT, a uni- or
bilateral neck dissection was performed in 18 patients in the RT group
and five in the RT-CT group (/> = 0.047), and two patients in the RT
group had an adenectomy. Otherwise surgery was reserved for salvage
of loco-regional failures.
Chemotherapy
In the initial patients chemotherapy was delivered sequentially prior to
starting RT. Apparently satisfactory tolerance led to a gradual shift
toward the administration of an increasing proportion of the chemo-
therapy concomitantly with RT. Thus in 10 cases chemotherapy was
administered only prior to, and in 25 concomitantly with RT, either
alone or with neoadjuvant and/or adjuvant chemotherapy.
Except for two patients treated with weekly carboplatin, all patients
received cisplatin (CDDP), associated with 5-fluorouracil (5-FU) in 28
patients, with epirubicin + bleomycin in four patients, and adminis-
tered alone in one patient. Twenty-two (63%) patients received three
cycles, nine (26%) two cycles, and two (6%) one cycle. In patients
receiving at least part of their chemotherapy concomitantly with RT,
chemotherapy consisted of CDDP and 5-FU in 21 patients (84%).
Fourteen patients received one cycle, and seven patients two cycles,
administered generally on the first and the fourth week of RT. CDDP
(100 mg/m ) was given as a rapid intravenous infusion followed by
Statistical methods
The actuarial overall and disease-free survival rates as well as actuarial
local and loco-regional control rates were calculated by using the
Kaplan-Meier method [19]. The Fisher's exact test, the unpaired t-
test, and the logrank test were used to assess for significant differences
between simple proportions, means, and survival curves respectively.
Results
All the patients completed the planned irradiation
schedule except one in the RT-CT group. All three treat-
ment interruptions due to acute toxicity occurred in the
RT-CT group (split duration 5, 17, and 35 days). The
median overall treatment time was 41 days (range 36-50
days) for the RT group and 39 days (range 37-79) for the
RT-CT group. The median tumor dose for both groups
was similar (69.9 Gy, range 62.5-72.9).
Morbidity
According to the RTOG grading system [20], all acute
reactions were grade 2 or more. The majority were grade
3 reactions, with only one patient in the RT group and
two patients in the RT-CT group presenting with grade 4
acute toxicity. The main acute toxicity parameters for
the two groups are displayed in Table 2. In the RT-CT
group, grade 3 dysphagia was more frequent with con-
comitant (64%) than with neoadjuvant (45%) chemo-
therapy administration.
According to the World Health Organization (WHO)
grading system [21], 12 patients (36%) in the RT-CT
group presented with grade 3-4 hematological compli-
cations. Grade 3 gastrointestinal complications were ob-
served in four patients, and grade 3 skin reactions in one
patient. Three patients presented with a vascular throm-
bosis requiring anticoagulation, three with alopecia and
one with hearing impairment.
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Figure 1. Schematic representation of the radiotherapy protocol.
Three patients in the RT group and one in the RT-CT
group died during the three months following radio-
therapy of causes not clearly related to tumor progres-
sion. One patient, who refused supportive care, died
of malnutrition; one malnourished patient died from
Candida septicemia; one patient died from pneumonia
as a consequence of severe laryngeal edema; and one
patient died from a massive oropharyngeal hemorrhage
in a setting of post-chemotherapy thrombopenia.
Seventy-three patients were evaluable for long-term
complications (patients with a minimum follow-up of
three months and with available data). Most complica-
tions were RTOG grade 2 (52% and 42% in the RT and
RT-CT groups, respectively). Grade 3-4 complications
were observed in 5% and 12% in the RT and RT-CT
groups, respectively (P = 0.4).
Clinical outcome
At last follow-up, 31 patients in the RT group and 17 in
the RT-CT group were still alive, and one patient in each
group was lost to follow-up (14 and 11 months). In
patients having died, head and neck cancer was consid-
ered the cause of death in 14 of 20 patients in the RT
group and 11 of 17 patients in the RT-CT group. The
median follow-up for the surviving patients was 21
months (range 2-60) and 31 months (range 4-54) for
the RT and RT-CT groups, respectively.
Local and locoregional control rates were estimated
for patients with a minimum follow-up of one year and
without taking into account the contribution of salvage
surgery. At three years actuarial local control was 70%
in the two groups and actuarial loco-regional control
was 57% and 66% for the RT and RT-CT groups,
respectively (P = 0.66). The three-year actuarial overall
survival was 56% and 47% (P = 0.99), and the three-year
disease-free survival was 53% and 60% for the RT and
the RT-CT groups, respectively (P - 0.8).
Discussion
Unconventional radiation fractionation schedules and
the association of chemotherapy with RT represent the
main innovative approaches currently under study for
the treatment of unfavorable head and neck cancers.
Progress in this area has been impeded by the problem
of unacceptable acute toxicity, and various strategies
have been developed to assure the feasibility of these
aggressive treatment programs. In the case of acceler-
ated RT schedules, tolerance has been variously im-
proved by reducing the total dose (very accelerated
continuous course), interposing a treatment gap (accel-
erated split course), or reducing the volume submitted to
accelerated fractionation (concomitant boost). On the
other hand, for combinations of chemo- and radiother-
apy, many investigators have preferred sequential or
alternating schedules, in order to avoid the toxicity asso-
ciated with the concomitant administration of the two
modalities. Moreover, chemotherapy has often been lim-
ited to single agents, and RT administered using standard
fractionation or using split course techniques. In con-
trast, the feasibility of concomitant chemotherapy and
continuous accelerated RT has not been extensively
investigated.
There is increasing evidence that locoregional control
can be improved through the use of various hyperfrac-
tionated and accelerated RT programs [1, 4, 6, 9, 22].
Considering the logistical convenience and the encour-
aging initial results of concomitant boost schedules [9],
a modified concomitant boost program was developed,
in which the 13 second daily fractions were given in a
progressively accelerated manner starting on day 12 of
the basic treatment. This schedule design was based on
the notion, as suggested by both experimental and
clinical data [23, 24], that cancer clonogen repopulation
may become significant as early as two weeks after
initiation of RT, and that the incremental dose required
to compensate for tumor proliferation might increase
progressively toward the end of treatment.
At the same time, and with the aim of increasing the
efficacy of this accelerated RT schedule, selected patients
with very advanced disease were given chemotherapy.
Initially chemotherapy was given sequentially before RT,
but since this mode of administration had come under
serious criticism [8, 11, 25], a decision was made to give
at least part of the chemotherapy concomitantly with
irradiation. The choice of 5-FU/CDDP was motivated
by the reported activity of this combination in head and
neck cancers [3, 12] and by the radiosensitizing proper-
ties attributed to CDDP [26, 27].
As expected from any accelerated RT program, the rate
of grade 3-4 acute reactions was high and was increased
by the adjunction of chemotherapy (Table 2). Indeed,
compared with the RT group, there was greater overall
acute toxicity and significantly more grade 3 dysphagia
in the RT-CT group, and patients receiving combined
treatment more frequently required hospitalization and
needed significantly more nutritional support. However,
it is the authors' impression that acute toxicities were
equally manageable in the two groups, particularly when
timely supportive care was provided. The most signifi-
cant therapeutic disadvantage of combined treatment
was the occasional disruption of RT delivery.
In this retrospective analysis, locoregional control,
disease-free survival, and overall survival were not sig-
nificantly different between the two groups. This appears
to be in contradiction to the results of some randomized
studies comparing concomitant chemoradiotherapy with
RT alone, which demonstrate significantly better loco-
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regional control [14—16], and suggest a statistically sig-
nificant improvement in survival with combined treat-
ment [28, 29]. However, as a result of patient selection,
the composition of the two groups in the present study
was not at all similar (Table 1). In particular, in the RT-
CT group there were fewer patients having had neck
dissections and a higher percentage of T3-T4 tumors. It
is thus impossible to draw conclusions from the current
study regarding the potential benefits of the combined
treatment.
In the absence of randomized comparisons the choice
of RT regimen for treating unfavorable head and neck
cancers will be determined by convenience, toxicity
profile, and the feasibility of administration simultane-
ously with effective antitumor agents. Although highly
accelerated continuous regimens are likely to be incom-
patible with such combined therapy, our initial clinical
results suggest that the concomitant boost program
described in the present paper can be administered
together with standard combination chemotherapy with
acceptable toxicity. The locoregional control obtained in
the present series of patients with stage III—IV disease is
encouraging. A confirmation of these results in prospec-
tive studies appears justified.
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